Unknown

Dataset Information

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial.


ABSTRACT:

Background

The POTENT trial compared the safety and efficacy of tipranavir/ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each with an optimized background regimen (OBR) in triple-class experienced HIV-1-infected patients with resistance to more than one protease inhibitor (PI).

Methodology/principal findings

POTENT was a prospective, open-label study of triple-class (PI, non-nucleoside reverse transcriptase inhibitors [NNRTI], nucleoside reverse transcriptase inhibitors [NRTI]), treatment-experienced, HIV-positive patients. Subjects were randomized to either TPV/r (500/200 mg twice daily) or DRV/r (600/100 mg twice daily) on a genotype-guided, investigator-selected OBR. CD4+ counts and HIV viral loads were assayed at key timepoints. The primary endpoint was time to virol

SUBMITTER: Elgadi MM 

PROVIDER: S-EPMC3585832 | biostudies-literature | 2011 Dec

REPOSITORIES: biostudies-literature